Stokovic Nikola, Ivanjko Natalia, Erjavec Igor, Breski Anita, Peric Mihaela, Vukicevic Slobodan
Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia.
Department of Pathology and Cytology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
Biomedicines. 2021 Oct 16;9(10):1487. doi: 10.3390/biomedicines9101487.
Autologous bone graft substitute (ABGS) containing rhBMP6 in autologous blood coagulum (ABC) with synthetic ceramics is a novel therapeutic solution for bone repair. The aim of this study was to investigate whether the application of Zoledronate (ZOL) with ABGS might enhance the properties of newly formed bone. The effect of ZOL on bone induction was tested in a rat subcutaneous implant model. ZOL bound to synthetic ceramics was added into ABGS implants, and the quantity, quality, and longevity of the induced bone were assessed by micro-CT, histomorphometry, and histology over a period of 365 days. Local use of ZOL in the ABGS implants with ceramics had no influence on the bone volume (BV) on day 14 but subsequently significantly increased BV on days 35, 50, 105, 140, and 365 compared to the control implants. Locally applied ZOL had a similar effect in all of the applied doses (2-20 µg), while its systemic use on stimulating the BV of newly induced bone by ABGS depended on the time of application. BV was increased when ZOL was applied systemically on day 14 but had no effect when applied on day 35. The administration of ZOL bound to ceramics in ABGS increased and maintained the BV over a period of one year, offering a novel bone tissue engineering strategy for treating bone defects and spinal fusions.
含重组人骨形态发生蛋白6的自体骨移植替代物（ABGS）与合成陶瓷混合于自体血凝块（ABC）中，是一种用于骨修复的新型治疗方案。本研究的目的是探讨唑来膦酸（ZOL）与ABGS联合应用是否能增强新形成骨的性能。在大鼠皮下植入模型中测试了ZOL对骨诱导的影响。将与合成陶瓷结合的ZOL添加到ABGS植入物中，并在365天的时间内通过显微计算机断层扫描、组织形态计量学和组织学评估诱导骨的数量、质量和寿命。在含陶瓷的ABGS植入物中局部使用ZOL在第14天时对骨体积（BV）没有影响，但与对照植入物相比，在第35天、50天、105天、140天和365天时显著增加了BV。局部应用的ZOL在所有应用剂量（2 - 20微克）下都有类似效果，而其全身应用对ABGS刺激新诱导骨BV的作用取决于应用时间。在第14天全身应用ZOL时BV增加，但在第35天应用时没有效果。在ABGS中与陶瓷结合的ZOL给药在一年时间内增加并维持了BV，为治疗骨缺损和脊柱融合提供了一种新的骨组织工程策略。
